Spinal Muscular Atrophy Clinical Trial
— JewelfishOfficial title:
An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric Patients With Spinal Muscular Atrophy
Verified date | June 2024 |
Source | Hoffmann-La Roche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multi-center, exploratory, non-comparative, and open-label study to investigate the safety, tolerability, PK, and PK/PD relationship of risdiplam in adults, children and infants with Spinal Muscular Atrophy (SMA) previously enrolled in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previously treated with nusinersen, olesoxime or AVXS-101.
Status | Active, not recruiting |
Enrollment | 174 |
Est. completion date | December 27, 2024 |
Est. primary completion date | December 27, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 60 Years |
Eligibility | Inclusion Criteria: - Confirmed diagnosis of 5q-autosomal recessive SMA - Previous enrollment in Study BP29420 (Moonfish) with the splicing modifier RO6885247 or previous treatment with any of the following: 1.) Nusinersen (defined as having received >= 4 doses of nusinersen, provided that the last dose was received >= 90 days prior to screening) or 2.) Olesoxime (provided that the last dose was received <= 12 months and >= 90 days prior to screening) or 3.) AVXS-101 (provided that the time of treatment was >= 12 months prior to screening) - Adequately recovered from any acute illness at the time of screening and considered well enough to participate in the opinion of the Investigator - For women of childbearing potential: negative blood pregnancy test at screening, agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs for at least 28 days after the final dose of study drug - For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm - For participants aged 2 years or younger at screening: 1.) Parent or caregiver of participant is willing to consider nasogastric, naso-jejunal or gastrostomy tube placement, as recommended by the Investigator, during the study to maintain safe hydration, nutrition and treatment delivery; 2.) Parent or caregiver of participant is willing to consider the use of non-invasive ventilation, as recommended by the Investigator during the study Exclusion Criteria: - Inability to meet study requirements - Concomitant participation in any investigational drug or device study - Previous participation in any investigational drug or device study within 90 days prior to screening, or 5 half-lives of the drug, whichever is longer with the exception of studies of olesoxime, AVXS-101, or nusinersen - Any history of gene or cell therapy, with the exception of AVXS-101 - Unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system diseases as considered to be clinically significant by the Investigator - Inadequate venous or capillary blood access for the study procedures, in the opinion of the Investigator - For patients aged < 2 years, hospitalization for a pulmonary event within 2 months prior to screening and pulmonary function not fully recovered at the time of screening - Lactating women - Suspicion of regular consumption of drugs of abuse - For adults and adolescents only, positive urine test for drugs of abuse or alcohol at screening or Day -1 visit - Presence of clinically significant electrocardiogram (ECG) abnormalities before study drug administration from average of triplicate measurement or cardiovascular disease - History of malignancy if not considered cured - For participants aged > 6 years, significant risk for suicidal behavior, in the opinion of the Investigator as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) - Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first dose administration - Recently initiated treatment for spinal muscular atrophy (within <6 weeks prior to enrollment) with oral salbutamol or another beta 2-adrenergic agonist taken orally - Any prior use of chloroquine, hydroxychloroquine, retigabin, vigabatrin or thioridazine, is not allowed - Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to risdiplam or to the constituents of its formulation - Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study - Recent history (less than one year) of ophthalmological diseases - Any prior use of an inhibitor or inducer of FMO1 or FMO3 taken within 2 weeks (or within 5 elimination half-lives, whichever is longer) prior to dosing |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Gent | Gent | |
Belgium | UZ Leuven Gasthuisberg | Leuven | |
France | Hopital Femme Mere Enfant; Medecine Physique et Readaptation Pediatrique ? L?ESCALE | Bron | |
France | Hopital Roger Salengro | Lille | |
France | CHRU de Montpellier, Hopital Gui de Chauliac; Service de Neuropediatrie | Montpellier | |
France | Hôpital Necker-Enfants Malades; Service de neuropédiatrie | Paris | |
France | Hopital des Enfants; Unite de Neurologie Pediatrique | Toulouse | |
Germany | Universitätsklinikum Essen; Klinik für Kinderheilkunde I | Essen | |
Germany | Universitätsklinikum Freiburg; Klinik für Neuropädiatrie und Muskelerkrankungen | Freiburg | |
Italy | IRCCS Istituto Giannina Gaslini; U.O.S.D. Centro di Miologia e Patologie Neurodegenerative | Genova | Liguria |
Italy | UOSD Malattie Neurodegenerative | Messina | Sicilia |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Unità Operativa Complessa di Neurologia | Milano | Lombardia |
Italy | IRCCS Ospedale Pediatrico Bambino Gesù; U.O. Malattie Neuromuscolari e Neurodegenerative | Roma | Lazio |
Italy | Policlinico Agostino Gemelli; Dipartimento di Neuropsichiatria Infantile | Roma | Lazio |
Netherlands | UMC Utrecht; Polkliniek Neuromusculaire ziekten | Utrecht | |
Poland | Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie | Warszawa | |
Switzerland | Universitäts-Kinderspital (UKBB) Neuropädiatrie | Basel | |
United Kingdom | Birmingham Heartlands Hospital | Birmingham | |
United Kingdom | UCL Institute of Child Health & Great Ormond Street Hospital for Children | London | |
United Kingdom | The Newcastle upon Tyne Hospitals NHS Foundation Trust | Newcastle upon Tyne | |
United States | Boston Childrens Hospital | Boston | Massachusetts |
United States | Columbia University Medical Center; The Neurological Institute of New York | New York | New York |
United States | Nemours Children's Hospital | Orlando | Florida |
United States | Stanford University Medical Center | Palo Alto | California |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Belgium, France, Germany, Italy, Netherlands, Poland, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Scale, V 4.0 | Baseline up to 5 years | ||
Primary | Percentage of Participants With Emergence or Worsening of Symptoms As Assessed Using Columbia Suicide Severity Rating Scale (C-SSRS) (Adult Version for Adults and Adolescents, Pediatric Version for Patients Aged 6-11 Years) | Baseline up to 5 years | ||
Primary | Percentage of Participants With Protocol Defined Clinically Significant Changes in Ophthalmological Assessments | Baseline up to 5 years | ||
Primary | Percentage of Participants With Protocol Defined Clinically Significant Changes in Neurological Assessments | Baseline up to 5 years | ||
Primary | Tanner Staging Among all Participants Aged From 9 to 17 Years | Baseline up to 5 years | ||
Primary | Mean Plasma Concentration of Risdiplam | Up to 2 years | ||
Primary | Maximum Plasma Concentration (Cmax) of Risdiplam | Up to 2 years | ||
Primary | Area Under the Plasma Concentration Versus Curve (AUC) of Risdiplam | Up to 2 years | ||
Primary | Concentration of Risdiplam at the End of Dosing Interval (Ctrough) | Up to 2 years | ||
Primary | Mean Plasma Concentration of Risdiplam Metabolite | Up to 2 years | ||
Primary | Cmax of Risdiplam Metabolite | Up to 2 years | ||
Primary | AUC of Risdiplam Metabolite | Up to 2 years | ||
Primary | Ctrough of Risdiplam Metabolite | Up to 2 years | ||
Secondary | SMN messenger Ribonucleic Acid (mRNA) Level in Blood | Up to 2 years | ||
Secondary | SMN Protein Levels in Blood | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04851873 -
Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA)
|
Phase 3 | |
Completed |
NCT03223051 -
Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Recruiting |
NCT05794139 -
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT02003937 -
Aerobic Training in Patients With Spinal Muscular Atrophy Type III
|
N/A | |
Not yet recruiting |
NCT00961103 -
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA)
|
N/A | |
Completed |
NCT00227266 -
Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
Completed |
NCT00374075 -
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy
|
Phase 1 | |
Enrolling by invitation |
NCT05539456 -
Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
|
||
Recruiting |
NCT05779956 -
Personalized Medicine for SMA: a Translational Project
|
||
Recruiting |
NCT03217578 -
Neonatal Spinal Muscular Atrophy (SMA) Screening
|
||
Recruiting |
NCT03300869 -
Natural History of Types 2 and 3 SMA in Taiwan
|
||
Completed |
NCT01703988 -
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02235090 -
Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting
|
N/A | |
Completed |
NCT02123186 -
Newborn Screening for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00756821 -
A Pilot Study of Biomarkers for Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT00004771 -
Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
|
Phase 2 | |
Recruiting |
NCT05366465 -
Quality of Life and Participation of the Adult With Spinal Muscular Atrophy in France
|
||
Recruiting |
NCT06310421 -
Spinal Muscular Atrophy Neonatal Screening Program
|